Yingying Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yingying Liu has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Dongxin Lv
Laboratory of Pharmacology & Toxicology, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, 510006, PR China
1 shared publication Gangfeng Zhao
Department of Clinical Medicine, Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, 310000, PR China
1 shared publication- Hongliang Liu
School of Life Sciences and Medicine, Shandong University of Technology, Zibo, P.R. China
1 shared publication - Hui Luo
School of Clinical Medicine, Hangzhou Normal University, Hangzhou 311121, China
1 shared publication Lin Bai
Key Laboratory of Human Disease Comparative Medicine, Ministry of Health, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences and Comparative Medical Center, Peking Union Medical College, Beijing, 100021, PR China
1 shared publicationNingzhi Zhang
Department of Cardiology, Shanghai Geriatric Medical Center, Shanghai, PR China
1 shared publication
Latest Publications
- 15 September 2024
- Published by Elsevier in Phytomedicine
- Vol. 135, 156055
Cardioprotective effects of polydatin against myocardial injury in HFD/stz and high glucose-induced diabetes via a Caveolin 1-dependent mechanism
- 15 September 2024
- Published by Elsevier in Phytomedicine
- Vol. 135, 156055
Cardioprotective effects of polydatin against myocardial injury in HFD/stz and high glucose-induced diabetes via a Caveolin 1-dependent mechanism
- Open Access
- 27 February 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (5) , 1883
The Potential Roles of Exosomes Carrying APP and Tau Cleavage Products in Alzheimer’s Disease
Alzheimer’s disease (AD) is the leading cause of dementia throughout the world. It is characterized by major amyloid plaques and neurofibrillary tangles (NFTs), which are composed of amyloid-β (Aβ) peptide and hyperphosphorylated Tau (p-Tau), respectively. Exosomes, which are secreted by cells, are single-membrane lipid bilayer vesicles found in bodily fluids and they have a diameter of 30–150 nm. Recently, they have been considered as critical carriers and biomarkers in AD, as they facilitate communication between cells and tissues by delivering proteins, lipids, and nucleic acids. This review demonstrates that exosomes are natural nanocontainers that carry APP as well as Tau cleavage products secreted by neuronal cells and that their formation is associated with the endosomal–lysosomal pathway. Moreover, these exosomes can transfer AD pathological molecules and participate in the pathophysiological process of AD; therefore, they have potential diagnostic and therapeutic value for AD and might also provide novel insights for screening and prevention of the disease.
- 27 February 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (5) , 1883
Open AccessThe Potential Roles of Exosomes Carrying APP and Tau Cleavage Products in Alzheimer’s Disease
Alzheimer’s disease (AD) is the leading cause of dementia throughout the world. It is characterized by major amyloid plaques and neurofibrillary tangles (NFTs), which are composed of amyloid-β (Aβ) peptide and hyperphosphorylated Tau (p-Tau), respectively. Exosomes, which are secreted by cells, are single-membrane lipid bilayer vesicles found in bodily fluids and they have a diameter of 30–150 nm. Recently, they have been considered as critical carriers and biomarkers in AD, as they facilitate communication between cells and tissues by delivering proteins, lipids, and nucleic acids. This review demonstrates that exosomes are natural nanocontainers that carry APP as well as Tau cleavage products secreted by neuronal cells and that their formation is associated with the endosomal–lysosomal pathway. Moreover, these exosomes can transfer AD pathological molecules and participate in the pathophysiological process of AD; therefore, they have potential diagnostic and therapeutic value for AD and might also provide novel insights for screening and prevention of the disease.